Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience

Injury

Volumn 47, Issue 10, 2016, Pages 2131-2137

  Zhu, Hongjian ^a   Fox, Erin E ^b   Baraniuk, Sarah ^a   Holcomb, John B ^b   Wade, Charles E ^b   Del Junco, Deborah J ^b   Tilley, Barbara C ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Blood product transfusion; Medication dispensing error; Ordered treatment regimens; Protocol adherence

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; HUMAN; MAJOR CLINICAL STUDY; MEDICATION ERROR; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD COMPONENT THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOLOGY; ERYTHROCYTE COUNT; MULTICENTER STUDY; PLASMA; PROCEDURES; THROMBOCYTE;

BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; CLINICAL PROTOCOLS; ERYTHROCYTE COUNT; GUIDELINE ADHERENCE; HUMANS; PLASMA;

EID: 84979735742     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/j.injury.2016.07.028     Document Type: Article

References (7)

1. [1] Alexander, J.H., Levy, E., Lawrence, J., Hanna, M., Waclawski, A.P., Wang, J., et al. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J 166:3 (2013), 559–565.
2. [2] James, K.L., Barlow, D., McArtney, R., Hiom, S., Roberts, D., Whittlesea, C., Incidence, type and causes of dispensing errors: a review of the literature. Int J Pharm Pract 17:1 (2009), 9–30.
3. [3] Spencer, M.G., Smith, A.P., A multicentre study of dispensing errors in British hospitals. Int J Pharm Pract 2:3 (1993), 142–146.
4. [4] Allan, E., Barker, K., Fundamentals of medication error research. Am J Health-Syst Pharm 47:3 (1990), 555–571.
5. [5] Holcomb, J.B., Tilley, B.C., Baraniuk, S., Fox, E.E., Wade, C.E., Podbielski, J.M., et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313:5 (2015), 471–482.
6. [6] Baraniuk, S., Tilley, B.C., Del Junco, D.J., Fox, E.E., Van Belle, G., Wade, C.E., et al. Pragmatic randomized optimal platelet and plasma ratios (PROPPR) trial: design, rationale and implementation. Injury 45:9 (2014), 1287–1295.
7. [7] Novak, D.J., Bai, Y., Cooke, R.K., Marques, M.B., Fontaine, M.J., Gottschall, J.L., et al. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the pragmatic, randomized optimal platelets and plasma ratios (PROPPR) trial. Transfusion 55:6 (2015), 1331–1339.